The lifetime risk of breast cancer for cis women is approximately 12%, while the lifetime risk for cis men is approximately 0.1% (Sonnenblick et al., 2018).
Research has shown that the lifetime risk of breast cancer for trans women on feminising hormone treatment is higher than the lifetime risk for cis men, but lower than the lifetime risk for cis women. Also, the lifetime risk of breast cancer for trans men is higher than the lifetime risk for cis men, but lower than the lifetime risk for cis women (de Blok et al., 2019).
This indicates that feminising hormone treatment with oestrogen is associated with an increased risk of breast cancer. Studies in postmenopausal cis women on hormone replacement therapy have suggested that the addition of synthetic progestin can increase the risk of breast cancer further (Beral, 2003; Colditz et al., 1995; Rossouw et al., 2002). However, there is no evidence that bioidentical progesterone is associated with any increased risk. Studies on hormone replacement therapy in postmenopausal cis women have shown that bioidentical progesterone is associated with a significantly lower risk of breast cancer than synthetic progestin (Asi et al., 2016; Fournier et al., 2008).
Research on trans women who developed breast cancer has shown that most of the tumours were positive for oestrogen and progesterone receptors (de Blok et al., 2019). Therefore, it is recommended that oestrogen and progesterone are not prescribed for people with active breast cancer, as there is a likelihood that the cancer will be sensitive to oestrogen and progesterone.
Special considerations are required for people who have BRCA1 or BRCA2 genotypes or family histories of breast cancer suggestive of BRCA1 or BRCA2 genotypes. BRCA1 and BRCA2 are genes which are associated with a substantially increased risk of breast cancer. The lifetime risk of breast cancer for cis women with BRCA1 or BRCA2 genotypes is estimated to be between 40% and 85%, while the lifetime risk for cis men with BRCA1 or BRCA2 genotypes is estimated to be between 1.2% to 6.8% (Pruthi et al., 2010; Tai et al., 2007).
Epidemiological evidence on the risk of breast cancer in trans people with BRCA1 or BRCA2 genotypes is lacking. However, a case report on a trans women with a BRCA1 genotype involved the continuation of feminising hormone treatment under informed consent (Colebunders et al., 2014). Given the potentially significant risk of breast cancer in people with BRCA1 or BRCA2 genotypes, it is strongly recommended that trans people with BRCA1 or BRCA2 genotypes receive genetic counselling and are fully informed of the risk before consenting to feminising hormone treatment. Trans women and transfeminine people with BRCA1 or BRCA2 genotypes on feminising hormone treatment are also advised to speak to their doctors about enhanced breast cancer screening programmes at younger ages and regular breast examinations.
A meningioma is a relatively rare tumour of the meninges which line the brain. It is usually benign and grows slowly.
There is evidence that the antiandrogen cyproterone acetate is associated with an increased risk of meningioma. In a study of 10,876 trans women, the risk of meningioma was 2.07 per 10,000 people per year in trans women who were taking cyproterone acetate, compared to 0 in trans women who were not taking cyproterone acetate. Further data on cis girls and cis women found that people who were taking cyproterone acetate were 5 times more likely to develop meningioma than people who were not taking cyproterone acetate. The risk of meningioma was greater with higher doses of cyproterone acetate (Weill et al., 2021).
Therefore, while the absolute risk of meningioma remains low, it is important to acknowledge that cyproterone acetate does increase the lifetime risk of developing meningioma. Apart from cyproterone acetate, there is no evidence that other antiandrogens or other hormonal treatments increase the risk of meningioma.
In people who have a prostate gland, there is a theoretical risk that exogenous testosterone could increase the risk and severity of prostate cancer (Michaud et al., 2015). However, this is inapplicable to people without prostates who are taking testosterone, such as trans men on masculinising hormone treatment.
There is no evidence that feminising hormone treatment in trans women is associated with an increased risk of prostate cancer. Recent studies have found that trans women on feminising hormone treatment have lower incidences of prostate cancer than cis men (Nash et al., 2018; Silverberg et al., 2017). And so, it can be concluded that feminising hormone treatment in trans women does not increase the risk of prostate cancer.
However, although feminising hormone treatment does not increase the risk of prostate cancer, it is important to recognise that trans women who have prostates can still get prostate cancer. The prostate is generally not removed in gender affirming surgery, and so the risk remains present in trans women who have had gender affirming surgery. Furthermore, there is some evidence that the diagnosis of prostate cancer may be more complicated in trans women who have had gender affirming surgery, because it may be more difficult to feel the prostate during a clinical examination (Tanaka et al., 2022).
To date, there is only one case report of endometrial cancer in a trans man (Urban et al., 2011). There is no evidence that masculinising hormone treatment increases the risk of endometrial cancer.
There have been some reported cases of ovarian cancer in trans men on masculinising hormone treatment (Dizon et al., 2006; Hage et al., 2000). However, there is no evidence that trans men on masculinising hormone treatment are at any increased risk of ovarian cancer compared to cis women.
A recent study found that trans women on feminising hormone treatment have similar incidences of testicular cancer to cis men (de Nie et al., 2022). Hence, there is no evidence that feminising hormone treatment increases the risk of testicular cancer.
Cervical cancer, penile cancer, and anal cancer tend to be caused by human papillomavirus infection, which is a sexually transmitted infection.
Gender affirming hormone treatment does not increase the risks of these cancers. Nonetheless, epidemiological evidence suggests that the trans population have higher incidences of these cancers than the cis population, due to disparities in social inclusion, healthcare access, economic stability, and support (Quinn et al., 2015).
Recommendations:
Aside from what has been discussed above, there is no evidence that gender affirming hormone treatment increases the risks of other cancers (Braun et al., 2017).